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Thirty-five patients >70 years of age with acute 
myocardial infarction (AMI) were treated with 
emergency percutaneous transluminal coronary an- 
gioplasty (PTCA). Seventeen (49%) patients re- 
ceived previous thrombolytic therapy: streptoki- 
nase (10 patients), tissue plasminogen activator (6) 
and combined tissue plasminogen activator and 
urokinase (1). Infarct-related artery patency was 
achieved in 26 patients (74%) after PTCA. Total 
in-hospital mortality was 34%. Univariate analysis 
showed a higher in-hospital mortality in patients 
with an occluded vessel after PTCA (78%) than in 
those patlents with a patent infarct-related artery 
(19%) (p = 0.003). Symptomatic coronary reocclu- 
sion occurred in 3 patients (15%) during the hospi- 
tal stay. Compared with emergency PTCA in 200 
consecutively treated patients <70 years of age, 
the in-hospital mortality was increased (34 vs 6%, 
p <O.OOl), and the primary success rate was re- 
duced (66 vs 90%, p <O.OOl). At a mean follow-up 
of 28 months, there has been a 13% out-of-hospi- 
tal mortality rate in the elderly patients (3 patients 
died). Of the 20 surviving patients, 14 are asymp- 
tomatic and 6 have class II angina. In conclusion, 
emergency PTCA for AMI in elderly patients is as- 
sociated with a decreased success rate and a high- 
er mortality rate. However, the in-hospital mortali- 
ty rate is not dissimilar to that in elderly AMI pa- 
tients treated with conventional therapy or 
thrombolytic therapy alone, and the postdischarge 
mortality rates are low. 
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efore the era of reperfusion, a number of studies in B the 1960s and 1970s showed a 30 to 50% in-hos- pital mortality rate for patients older than 70 
years of age with acute myocardial infarction (AMI).1%2 
While thrombolytic therapy has been shown to reduce 
mortality in younger patients, it has been less effica- 
cious in older patients. 3,4 In the Gruppo Italian0 per lo 
Studio della Streptochinasi nell’Infarto Miocardico 
(GISSI) randomized trial of intravenous streptokinase, 
there was no apparent mortality reduction in the elderly 
subset of patients.3 Moreover, Lew et al4 found that pa- 
tients 75 years or older had a lo-fold higher in-hospital 
mortality rate and l-year mortality rate than patients 
<75 years of age after treatment with intravenous 
streptokinase. Recently, percutaneous transluminal cor- 
onary angioplasty (PTCA) has emerged as a new inter- 
vention for reperfusion during AMI. Limited data exist 
regarding the efficacy of PTCA in the elderly. The pre- 
sent pilot study defines the clinical outcomes, technical 
success rate and morbidity and mortality of emergency 
PTCA for patients >70 years of age with AMI, and 
compares these results with those in patients <70 years 
of age similarly treated. 
METHODS 
Study patients: At our institution, all patients with 
evidence of AM1 and fulfillment of predefined criteria 
from January 1984 to December 1986 were taken to the 
cardiac catheterization laboratory on an emergency ba- 
sis. Criteria for acute catheterization were: (1) presence 
of chest pain consistent with AMI; (2) electrocardio- 
graphic evidence of AM1 as indicated by 11 mm ST 
elevation or depression in 2 consecutive leads; and (3) 
<6 hours since onset of chest pain or persistent pain 
after 6 hours. Forty-nine patients 270 years of age had 
emergency cardiac catheterization for AMI. Thirty-five 
of these patients had acute PTCA performed and they 
comprise the study group. PTCA was not performed in 
14 patients. Eight patients had a patent vessel and se- 
vere, multiple vessel coronary disease and they under- 
went coronary artery bypass surgery. Four patients bad 
evidence of extensive angiographic filling defect(s) and 
received intracoronary thrombolytic therapy. Two pa- 
tients had a diffusely diseased infarct vessel and were 
believed to be unsuitable for PTCA. The comparison 
group consisted of 200 consecutive patients with AM1 
<70 years of age who were concurrently treated with 
PTCA from May until December 1986. No patient was 
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TABLE I Findings in the Patients Studied 
Systolic Diseased Peak Time to 
Pt. Age BP Kbp Vessels EF LVEDP Lytic PTCA CK PTCA Clinical 
No. (yrs). Sex (mm Hg) Class IRCA (n) W) (mm Hg) Therapy Outcome (IU/liter) (hrs) Outcome 
1 74. M 112 I LAD 3 22 35 0 P. Success 11,200 9 Died 
2 70, F 135 I R 1 62 25 0 Success 288 4 Sun/wed 
3 74, M 110 I R 3 39 12 IC SK Success 1,536 7 Survived 
4 78, F 130 IV LC 1 53 18 0 Failure 426 8 Survwed 
5 74, M 86 III LAD 1 - 15 IC SK Failure 8,160 4 Died 
6 81, M 125 I LAD 3 0 Vessel occl. - 4 Died 
7 74, M 110 I R 3 45 16 0 Failure 1,040 3 Sun/wed 
8 72, F 135 II R 2 69 20 0 Success 2,067 5 Survwed 
9 71, M 122 I R 3 47 20 0 P. Success 2,135 4 Survived 
10 80, F 144 II LAD 2 0 Success 4.82 3 Survwed 
11 71, F 158 I R 3 71 30 IV SK P. Success 1,266 6 Died 
12 71, M 115 II R 1 47 16 IV SK Success 1,395 3 Survwed 
13 72, F 90 IV LAD 3 28 30 0 P. Success 6,900 6 Survived 
14 77, M 130 II R 1 55 20 0 Vessel occl. - 3 Died 
15 71, M 180 I R 2 42 12 0 Success 2,060 6 Survived 
16 72, M 130 I IAD 1 27 30 IV SK Success 323 8 Survived 
17 70, M 94 I R 1 55 15 IV SK Vessel occl. 2,400 4 Survived 
18 70, F 60 IV LAD 3 0 Failure 3,786 15 Died 
19 70, M 100 II LAD 1 41 36 0 Failure 3,960 14 Died 
20 75, M 80 IV R 2 - 32 IV SK Success - 3 Died 
21 73, F 100 II LC 3 35 15 IC SK Success 972 4 Survived 
22 73, M 130 I LAD 1 47 26 t-PA Success 5,120 6 Died 
23 73. M 150 II LAD 3 25 28 IV SK Failure 4,140 10 Survwed 
24 91, F 100 II LAD 3 - - 0 Failure - 2 Died 
25 70, M 110 I LAD 1 58 17 t-PA Vessel occl. - 4 Survived 
26 70. M 130 I R 1 52 26 t-PA Success 3,540 5 Survived 
27 76, F 85 IV LC 3 - 32 0 Success 12,120 4 Died 
28 75, F 80 IV LAD 3 18 39 0 Failure 1,645 6 Died 
29 70, M 120 I R 2 61 24 t-PA Success 519 3 Survived 
30 76, M 140 Ill LAD 3 64 24 t-PA Success 2,630 6 Survived 
31 78, M 95 I R 3 40 21 0 P. Success 703 4 Survived 
32 72, M 102 I R 3 73 14 t-PA P. Success 2,120 6 Survived 
33 70. M 103 I LC 1 77 11 IV SK Success 530 4 Survived 
34 82, M 98 I R 3 60 24 0 P. Success - 3 Survived 
35 74, M 120 I IAD 1 48 38 t-PA + UK P. Success 5,580 6 Survived 
BP = blood pressure; CK = creatine kinase; EF = qectlon fraction; IRCA = Infarct-related coronary artery; LAD = left antenor descending, LC = left wcumflex, LVEDP = left 
Ventricular end-dlastohc pressure; Occl. = occlusion; P = partial (>50% residual stenosis), PTCA = coronary angloplasty; R = n&t; SK = streptokinase; t-PA = t&sue plasmlnogen ac- 
tlvator: UK = uroklnase: - = not avatlabk. 
excluded from the study because of age or presence of 
cardiogenic shock. Cardiogenic shock was defined as 
systolic blood pressure <80 mm Hg that was unrespon- 
sive to volume expansion. 
Coronary angioplasty protocol: In the emergency 
room, 15 patients received thrombolytic therapy and all 
patients received sublingual or intravenous nitroglycerin 
and morphine sulfate for pain. Patients were then trans- 
ferred directly to the cardiac catheterization laboratory. 
The cardiac catheterization laboratory team was on call 
24 hours a day and the operators had performed more 
than 200 elective and at least 50 emergency PTCA pro- 
cedures. 
Vascular access was obtained through the femoral 
artery. Intravenous heparin was administered: 5,000 U 
in patients receiving thrombolytic therapy and 10,000 U 
in the other patients. Arteriography of the infarct-relat- 
ed vessel was performed first, followed by arteriography 
of the uninvolved vessel. Left ventriculography was per- 
formed in patients who were sufficiently stable to un- 
dergo the procedure safely. PTCA was then performed 
in patients when clinically indicated. All patients re- 
ceived intravenous heparin for a minimum of 24 hours 
after PTCA. Total creatine kinase and isoenzymes were 
measured in all patients. 
Follow-up: After PTCA, all patients were treated 
with aspirin, 325 mg a day, and a calcium antagonist. 
An attempt to perform coronary arteriography was 
made before discharge. Telephone follow-up was ob- 
tained at 6-month intervals. 
RESULTS 
Forty-nine patients >70 years of age with AM1 pre- 
sented between January 1984 and December 1986. 
PTCA was performed in 35 patients and they comprise 
the study population. The reasons for not performing 
PTCA in the other 14 patients were provided in the 
Methods section. Seventeen patients (49%) were treated 
with thrombolytic therapy before emergency PTCA. 
Eight patients received intravenous streptokinase, 2 in- 
tracoronary streptokinase, 6 intravenous tissue plasmin- 
ogen activation and 1 patient combined intravenous tis- 
sue plasminogen activator and urokinase. 
Demographic characteristics of the patient popula- 
tion are listed in Table I. Of note, most patients present- 
ed to the catheterization laboratory and had PTCA per- 
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formed within 6 hours from the onset of chest pain. Sev- 
en patients (20%) had PTCA performed after 6 hours 
from symptom onset. Eight patients (23%) had PTCA 
performed within 3 hours of the onset of chest pain. 
Seventeen patients (49%) received thrombolytic therapy 
before PTCA. Upon presentation to the catheterization 
laboratory, the mean systolic blood pressure was 117 f 
24 mm Hg. Eight patients were in Killip class III or IV 
at presentation and the mean Killip class was 1.9 f 1.1~ 
Six patients (18%) were in cardiogenic shock before 
catheterization. All patients had admission history, elec- 
trocardiographic changes and subsequent enzymatic ev- 
idence confirming the diagnosis of AMI. Thirty-two pa- 
tients had ST elevation and 3 patients had marked ante- 
rior ST depression, with prominent R waves suggesting 
posterior wall infarction. Electrocardiographic changes 
had an anterior distribution in 17 patients (49%) and an 
inferior or lateral distribution in 18 patients (5 1%). 
Catheterization results: Cardiac catheterization was 
performed and the infarct artery was identified in all 
patients. The infarct vessel was the left anterior de- 
scending in 15 patients, the left circumflex in 4 and the 
right coronary artery in 16 patients. Before PTCA, the 
infarct artery was patent in 18 patients (51%). The re- 
sidual diameter stenosis in these 18 patients was 77 f 
11%. Of the 18 patients with a patent infarct-related 
vessel, 10 had received thrombolytic therapy, 1 achieved 
patency during baseline contrast injections and 7 pa- 
tients had a patent artery without thrombolytic therapy 
before the coronary angiography. 
As shown in Table I, most patients had multivessel 
coronary artery disease including 3-vessel disease in 17 
patients (49%). Twenty-eight patients had left ventric- 
ulography performed and the mean ejection fraction 
was 48 f 16%. The patients who did not have determi- 
nation of left ventricular end-diastolic pressure or left 
ventriculography were hemodynamically unstable and 
represented patients with poor left ventricular function. 
Technical results: Figure 1 shows the technical re- 
sults of the acute coronary angioplasty. Of the 35 pa- 
tients in the study population, 26 (74%) had a patent 
artery following PTCA. Patency was achieved via 
PTCA in 23 patients for an overall recanalization suc- 
cess rate of 66%. However, 15 patients had a postpro- 
cedural residual stenosis of <50% but 8 patients had a 
postprocedural stenosis of >50%. In 2,patients with a 
patent infarct vessel and high grade stenosis, there was 
failure to cross the lesion. In 1 patient, patency was 
maintained after abrupt closure with the use of an auto- 
perfusion catheter. This patient subsequently underwent 
emergent bypass surgery. 
Nine patients had an occluded infarct artery after 
PTCA. In 6 of 17 patients with an initially occluded 
vessel, the coronary angioplasty procedure failed to 
open the vessel. In 3 patients with an initially patent 
vessel, there was abrupt closure during the PTCA pro- 
cedure with failure to regain patency. 
The number of patients is too small to consider tech- 
nical success by method(s) of reperfusion. Nonetheless, 
of the 17 patients who received thrombolytic therapy, 4 
(17%) died in the hospital compared with 8 (44%) of 18 
patients who were treated with PTCA alone (p = 
0.193). Only 1 (6%) of 17 patients receiving thrombo- 
lytic therapy developed cardiogenic shock during or af- 
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FlCURE 1. Te&nkal results 
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ter PTCA. Conversely, 5 (28%) of 18 patients undergo- 
ing PTCA alone developed cardiogenic shock and all 
subsequently died (p = 0.086). 
Clinical course: Four patients developed recurrent 
chest pain after PTCA suggestive of acute reocclusion 
and underwent emergency repeat coronary angiogra- 
phy. Three patients were found to have an occluded in- 
farct vessel and 1 patient had restenosis but preserved 
flow. PTCA was successfully repeated in the patient 
with restenosis. In 2 patients, repeat PTCA failed to 
open the infarct-related vessel and in 1 patient repeat 
PTCA was not attempted. 
Nine patients underwent bypass surgery during their 
hospital stay; 4 patients urgently within 24 hours of the 
acute catheterization and 5 patients electively within 7 
to 10 days. Only 1 of these patients (11%) subsequently 
died during the hospital course from refractory ventric- 
ular arrhythmia. 
Mortality and morbidity: Twelve patients (34%) 
died during their hospital stay. Ten patients died of car- 
diogenic shock and 2 of refractory arrhythmia. Six pa- 
tients developed cardiogenic shock during or after the 
PTCA and all subsequently died. Four of the 6 patients 
presenting with cardiogenic shock died. 
Four patients developed congestive heart failure, de- 
fined as rales half way up the posterior chest field re- 
quiring long-term diuretic therapy. Five patients had 
major peripheral vascular complications. Three patients 
required surgical repair of the femoral artery including 
2 patients with femoral artery occlusion and 1 patient 
with an arteriovenous fistula. The 2 other patients had 
substantial blood loss (>2 units of blood) from the peri- 
access site. 
Predictors of in-hospital mortality: Univariate anal- 
ysis was performed with a number of variables in an 
attempt to predict mortality in this group of elderly pa- 
tients undergoing emergency PTCA. Cardiogenic shock 
on presentation, age >75 years and anterior AM1 had a 
trend of an increased mortality. Importantly, the 9 pa- 
tients with an occluded vessel after coronary angioplasty 
had a 78% in-hospital mortality rate; this was signifi- 
cantly higher than those 26 patients with a patent vessel 
whose mortality rate was 19% (p = 0.003). No other 
variable was found to be predictive of mortality. 
Months 
FIGURE 2. Survival analysis of the study group of 35 
patients. 
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Comparison with younger patients: These PTCA 
results in the elderly were compared with a group of 
200 consecutive patients <70 years of age with AM1 
similarly treated at the University of Michigan from 
May until December 1986. The mortality rate in pa- 
tients <70 years of age with AM1 treated with PTCA 
was 6% (12 of 200) vs 34% (12 of 35) in elderly patients 
(p <O.OOOl). PTCA was technically more difficult in 
the elderly patients: the primary success rate was 18 1 of 
200 (90%) in the younger patients compared with 25 of 
35 (66%) in patients >70 years of age (p <O.OOl). 
Repeat catheterization: Eighteen patients had re- 
peat coronary arteriography performed during their 
hospital course. In addition, 4 patients had an emergen- 
cy repeat catheterization performed for recurrent ische- 
mia. All 4 patients were found to have an occluded in- 
farct-related artery and 3 of these patients subsequently 
died. 
Thus, 14 of 23 (61%) surviving patients had repeat 
coronary angiograms performed before hospital dis- 
charge. Thirteen patients had a patent infarct-related 
artery and 1 patient had silent reocclusion. Of the 9 
patients without repeat arteriography, 4 had bypass sur- 
gery, 2 had a negative exercise treadmill test and in 3 
patients a clinical decision was made not to repeat cath- 
eterization. 
Long-term follow-up: Of the 23 surviving patients, 
22 (96%) have been followed through May 1,1988, and 
all patients have been followed for a minimum of 18 
months. The mean follow-up is 28 f 12 months. As 
Figure 2 illustrates, the vast preponderance of deaths 
occurred in the hospital. In the 23 patients discharged 
from the hospital, there have been 3 additional deaths in 
the subsequent follow-up period. One patient died 2 
months post-AM1 secondary to congestive heart failure. 
Two patients did well post-AM1 but died suddenly at 19 
and 26 months post-AMI. Of the 20 surviving patients, 
14 are asymptomatic and 6 have class II angina. 
DISCUSSION 
Scant evidence exists regarding the role of PTCA in 
the elderly patient. In this study of emergency PTCA in 
elderly patients with evolving AMI, a higher mortality 
rate was demonstrated compared with historical control 
patients (34 vs 6%) <70 years of age who were similarly 
treated. This higher mortality was associated with a 
high incidence of peri-AM1 complications including 3 
major peripheral vascular complications requiring vas- 
cular surgery. While acute PTCA in these elderly pa- 
tients resulted in significant morbidity and mortality, 
the lack of a concurrent control group precludes making 
definitive conclusions regarding the benefit to risk ratio 
in such patients. Moreover, the group of patients in the 
present study was complicated, as evidenced by the 17% 
rate of cardiogenic shock at presentation. 
Treatment of AM1 in the elderly is a difficult prob- 
lem. Norris et al’ reported a 42% in-hospital mortality 
in 212 patients >70 years of age hospitalized for AM1 
from 1967 to 1968 in Auckland, New Zealand. They 
developed a coronary prognostic index and found age to 
be the most important predictor of in-hospital mortality 
I. Latting et al2 reported their experience with 
175 patients age 270 years admitted with ANT in At- 
lanta, Georgia, from 1971 to 1977. The in-hospital mor- 
tality rate in these patients was 32% compared with 
8.2% in patients younger than 70 years. The leading 
cause of death in the elderly patients was cardiogenic 
shock. 
The poor prognosis in elderly patients with AM1 
provided the impetus to treat these high risk patients 
with thrombolytic agents. The GISSI Trial showed no 
significant improvement in mortality in elderly patients 
treated with intravenous streptokinase.3 Over 1,200 pa- 
tients >75 years of age were randomized to intravenous 
streptokinase or placebo. While there was a slight trend 
for reduced mortality in streptokinase-treated patients 
(29 vs 33%), this was not statistically significant. Lew et 
al4 recently reported a 1 O-fold higher in-hospital mortal- 
ity rate for 24 patients 75 years or older with AMI. The 
elderly patients had a 33% mortality rate compared 
with 3% in the 96 patients younger than 75 years simi- 
larly treated. All patients were treated with intravenous 
streptokinase within 3 hours of symptom onset. These 
problems with thrombolytic intervention suggest that a 
strategy that avoids the risks of bleeding complications 
may be particularly advantageous in the elderly popula- 
tion. 
The poor in-hospital prognosis in our patients was 
related in part to technical difficulties with PTCA. The 
PTCA success rate in the elderly patients was only 66% 
compared with 90% in younger patients similarly treat- 
ed at our institution. Several other recent studies in 
younger patients have also reported coronary angio- 
plasty success rates of 80 to 90% in the setting of 
AML5-‘* Therefore, elderly patients not only have a 
poor prognosis on the basis of their increased age, but 
their vessels appear to be less amenable to PTCA. We 
examined a number of variables in an attempt to find 
predictors of in-hospital mortality in our patient popula- 
tion. As expected, age more than 75 years, cardiogenic 
shock and anterior infarction all tended to be associated 
with an increased mortality. Importantly, the only vari- 
able clearly predictive of mortality was the presence of 
an occluded vessel after PTCA. 
The importance of a patent vessel after AM1 has 
been shown in the Western Washington Trial.13 A re- 
cent report by Mathey et all4 has also documented a 
correlation between infarct artery patency and long- 
term survival. Our data also suggest that a patent in- 
farct artery may be important for short-term survival in 
elderly patients with AMI. 
While acute coronary angioplasty did not appear to 
have a favorable impact on in-hospital survival in elder- 
ly patients with AMI, these patients had a very low 
postdischarge mortality. In the first 6 months after hos- 
pital discharge, there was only 1 death in 23 patients 
(4% mortality rate). At a mean follow-up of 28 months, 
there were only 3 deaths (13% mortality rate) in these 
elderly high risk patients. This compares very favorably 
with historical controls. In 60 patients more than 70 
years of age discharged from the hospital, Beaune et 
all5 reported a 17% 6-month mortality. Rapaport et alI6 
followed 33 elderly patients after discharge from hospi- 
tal after AM1 and found a 40% l-year mortality rate. 
In the present study, we cannot exclude that emergency 
PTCA led to an acceleration of the in-hospital mortali- 
ty, creating a false impression of a favorable long-term 
outlook. 
This relatively benign prognosis following discharge 
after reperfusion therapy has been previously demon- 
strated in younger patients. Stack et als9 have reported 
similarly low out-of-hospital 6- and 1Zmonth mortality 
rates. In addition to a low mortality rate after infarc- 
tion, these patients had very low morbidity after dis- 
charge. Of the surviving patients, 14 of 20 (70%) are 
asymptomatic at a minimum 12-month follow-up and 
no patients have class III or IV angina symptoms. 
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